However, a recent retrospective study involving 529 patients with chronic hepatic dysfunction, including 105 cirrhotic patients who underwent PD at high-volume institutions, indicated that portal hypertension, prothrombin activity <70%, serum AST > 50 IU/L, and APRI greater than 1.0, are associated with an increase in patient mortality [15]. The gene discussed is F2; the disease is liver disorder.